Program Leaders
Program Leaders
批准号:
8733554
负责人:
MARY M. ZUTTER
金额:
$7.49万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-09-01 至 2015-08-31
关键词:
Basic ScienceCancer Center Support GrantChargeClinical SciencesCollaborationsEvaluationFundingMalignant NeoplasmsPilot ProjectsPlayPostdoctoral FellowPreventionProcessPublicationsRecommendationResearchResource SharingRoleThe Vanderbilt-Ingram Cancer Center at the Vanderbilt UniversityUpdateauthorityfallsmeetingsmemberpopulation basedprogramsprospective
中文摘要
研究项目领导委员会(RPLC)-研究项目领导委员会(RPLC)在每月的第一个星期四开会,讨论与VICC内的研究机会和需求相关的问题。会议由基础科学研究计划主任兼副主任共同主持。其他成员包括All Research
项目负责人和共同负责人、副主任、临床科学研究项目副主任、预防、控制和以人口为基础的研究副主任、共享资源副主任、CCSG行政副主任和荣休主任。
这是一个重要的论坛,项目领导人在其中交流关于方案间和方案内研究举措的信息,并提供关于每个方案正在进行的高影响力研究的最新情况。
在这些会议期间,为新的或修改的共享资源、招聘、方案间协作和其他活动进行规划,以加强方案。RPLC的另一项重要职责是审查VICC的新成员申请,并向主任提出建议。会籍
提交的申请详细说明了未来成员与癌症相关的活动。RPLC对申请是否符合VICC成员标准进行评估,然后委员会对申请者进行评判
是否适合分配到适当的研究计划,并向主任提出建议,主任拥有任命成员的最终权力。RPLC还对VICC成员进行年度审查,并评估与癌症相关的资金和出版物、计划参与情况和癌症
每个成员的协作。最近一次评价发生在2008年秋季。区域可持续发展委员会在审查CCSG试点项目申请方面也发挥了重要作用。RPLC为应用程序选择审核者,并在所有审查都已返回后对应用程序进行排名。这个排名过程很重要
由于大多数年份只有15%-20%的提交申请可以获得资助。
英文摘要
Research Proqram Leaders Committee (RPLC) - The RPLC meets on the first Thursday of each month to discuss issues relevant to research opportunities and needs within the VICC. The meeting is co-chaired by the Director and Associate Director for Basic Science Research Programs. Other members include all Research
Program Leaders and Co-Leaders, the Deputy Director, the Associate Director of Clinical Science Research Programs, the Associate Director for Prevention, Control and Population-Based Research, the Associate Director for Shared Resources, the Associate Director for CCSG Administration, and the Director Emeritus.
This is an important forum in which program leaders exchange information about inter- and intra-programmatic research initiatives and provide updates about ongoing high impact research in each of the programs.
Planning for new or modified shared resources, recruitments, inter-programmatic collaborations and other activities to enhance the programs occurs during these meetings. Another important charge of the RPLC is to review new requests for membership in VICC and to make recommendations to the Director. Membership
applications are submitted detailing the cancer-related activities of prospective members. The RPLC evaluates the application for compliance with VICC membership criteria, the committee then judges the applicant for
suitability for assignment to the appropriate research program and a recommendation is made to the Director, who has ultimate authority in appointing members. The RPLC also conducts an annual review of the VICC membership and assesses cancer-relevant funding and publications, program participation and cancer
collaborations for each member. The most recent evaluation occurred in the fall of 2008. The RPLC also plays an important role in review of CCSG Pilot Project applications. The RPLC selects reviewers for the applications and ranks the applications after all reviews have been returned. This ranking process is important
as most years only 15-20% of submitted applications can be funded.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Program Leaders
-
批准号:8180520
-
项目类别:
-
资助金额:$19.99万
-
财政年份:2010
-
负责人:MARY M. ZUTTER
-
依托单位:
Human Tissue Aquisition and Pathology Shared Resource
-
批准号:8180573
-
项目类别:
-
资助金额:$24.32万
-
财政年份:2010
-
负责人:MARY M. ZUTTER
-
依托单位:
The alpha2beta1 Integrin and Tumor Metastasis
-
批准号:8403773
-
项目类别:
-
资助金额:$29.04万
-
财政年份:2009
-
负责人:MARY M. ZUTTER
-
依托单位:
The alpha2beta1 Integrin and Tumor Metastasis
-
批准号:8206619
-
项目类别:
-
资助金额:$30.9万
-
财政年份:2009
-
负责人:MARY M. ZUTTER
-
依托单位:
The alpha2beta1 Integrin and Tumor Metastasis
-
批准号:7744056
-
项目类别:
-
资助金额:$31.85万
-
财政年份:2009
-
负责人:MARY M. ZUTTER
-
依托单位:
The alpha2beta1 Integrin and Tumor Metastasis
-
批准号:8009795
-
项目类别:
-
资助金额:$30.9万
-
财政年份:2009
-
负责人:MARY M. ZUTTER
-
依托单位:
The alpha2beta1 Integrin and Tumor Metastasis
-
批准号:7576626
-
项目类别:
-
资助金额:$31.85万
-
财政年份:2009
-
负责人:MARY M. ZUTTER
-
依托单位:
Unexpected Roles for the alpha2beta1 Integrin
-
批准号:7389503
-
项目类别:
-
资助金额:$28.75万
-
财政年份:2005
-
负责人:MARY M. ZUTTER
-
依托单位:
Unexpected Roles for the alpha2beta1 Integrin
-
批准号:7585208
-
项目类别:
-
资助金额:$28.75万
-
财政年份:2005
-
负责人:MARY M. ZUTTER
-
依托单位:
Unexpected Roles for the alpha2beta1 Integrin
-
批准号:6959343
-
项目类别:
-
资助金额:$30.0万
-
财政年份:2005
-
负责人:MARY M. ZUTTER
-
依托单位:
Unexpected Roles for the alpha2beta1 Integrin
-
批准号:7214678
-
项目类别:
-
资助金额:$28.74万
-
财政年份:2005
-
负责人:MARY M. ZUTTER
-
依托单位:
Unexpected Roles for the alpha2beta1 Integrin
-
批准号:7082057
-
项目类别:
-
资助金额:$29.49万
-
财政年份:2005
-
负责人:MARY M. ZUTTER
-
依托单位:
The alpha 2 beta 1 Integrin: Innate Immunity to Pathogens & Tumors
-
批准号:7737055
-
项目类别:
-
资助金额:$33.07万
-
财政年份:2003
-
负责人:MARY M. ZUTTER
-
依托单位:
The a2b1 Integrin: Innate Immunity to Pathogens & Tumors
-
批准号:6993561
-
项目类别:
-
资助金额:$32.81万
-
财政年份:2003
-
负责人:MARY M. ZUTTER
-
依托单位:
The alpha 2 beta 1 Integrin: Innate Immunity to Pathogens & Tumors
-
批准号:8074980
-
项目类别:
-
资助金额:$32.84万
-
财政年份:2003
-
负责人:MARY M. ZUTTER
-
依托单位:
The a2b1 Integrin: Innate Immunity to Pathogens & Tumors
-
批准号:6836562
-
项目类别:
-
资助金额:$33.6万
-
财政年份:2003
-
负责人:MARY M. ZUTTER
-
依托单位:
The alpha2beta1 Integrin: Innate Immunity to Pathogens & Tumors
-
批准号:7161705
-
项目类别:
-
资助金额:$31.86万
-
财政年份:2003
-
负责人:MARY M. ZUTTER
-
依托单位:
The alpha 2 beta 1 Integrin: Innate Immunity to Pathogens & Tumors
-
批准号:8265298
-
项目类别:
-
资助金额:$32.85万
-
财政年份:2003
-
负责人:MARY M. ZUTTER
-
依托单位:
The a2b1 Integrin: Innate Immunity to Pathogens & Tumors
-
批准号:6694037
-
项目类别:
-
资助金额:$33.6万
-
财政年份:2003
-
负责人:MARY M. ZUTTER
-
依托单位:
The alpha 2 beta 1 Integrin: Innate Immunity to Pathogens & Tumors
-
批准号:7884569
-
项目类别:
-
资助金额:$33.07万
-
财政年份:2003
-
负责人:MARY M. ZUTTER
-
依托单位:
海外基金